Does high SHBG reduce free testosterone even when total testosterone is high?

In aging men, changes in sex hormone-binding globulin (SHBG) levels can significantly disrupt androgen status, decoupling total testosterone levels from actual tissue-level activity.

Clinical implications of elevated SHBG

• Functional deficiency: High SHBG binds circulating testosterone with high affinity, reducing the unbound, bioavailable fraction. This can precipitate functional hypogonadism—characterized by symptoms like erectile dysfunction and fatigue—even when total testosterone concentrations remain deceptively normal or elevated.
• Diagnostic accuracy: Because of this binding dynamic, assessing androgen status solely through total testosterone is insufficient; accurate diagnostic evaluation requires direct measurement of the free hormone fraction, preferably utilizing equilibrium dialysis.

Mechanistic pathways of androgen signaling

• Classical restriction: According to the free hormone hypothesis, systemic elevations in SHBG limit passive cellular diffusion. This restricts the available unbound pool of testosterone, reducing classical androgen receptor (AR) transcription. In vivo transgenic mouse models expressing human SHBG validate this systemic restriction.
• Active endocytosis: Conversely, in specific tissues expressing the multi-ligand endocytic receptor megalin (such as the prostate and kidney), the SHBG-testosterone complex is actively internalized via clathrin-dependent endocytosis rather than being excluded.
• Membrane-initiated signaling: Independent of passive diffusion, SHBG can bind to its specific cell-surface receptor (R_SHBG). This interaction triggers intracellular cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) signaling cascades, non-genomically amplifying downstream AR transcriptional activity.

Bottom line

• High SHBG reduces biologically active free testosterone, limiting systemic androgen signaling even in the presence of high total testosterone; however, this restrictive effect is modulated in specific target tissues by active megalin-mediated endocytosis and R_SHBG membrane signaling.